PARIS, France, November 28, 2022 at 8:30 a.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today today the resignation of Dr. David Horn SOLOMON from his position as Chief Executive Officer and Director of the Company.
During the Board of Directors which met on November 27, 2022, Dr. David Horn SOLOMON tendered his resignation, with immediate effect, from his duties as Chief Executive Officer and Director of Pharnext SA. The Board expressed its thanks to Dr. David Horn SOLOMON for his contributions.